Clinical significance of serum osteopontin levels in lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Clinical significance of serum adipokines levels in lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
The clinical significance of serum VEGF C, VEGF D and sVEGFR2 concentration in lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Relation between bone metastasis in lung cancer and serum IL-6 levels Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008
Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Comparison of the serum soluble IL-2 receptor levels in the differential diagnosis of pulmonary tuberculosis and lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003
The levels of osteoprotegerin (OPG), interleukin 18 (IL-18) and soluble interleukin 2 receptor (sIL-2R) in serum during chemotherapy of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
The clinical significance of serum osteoprotegerin (OPG) and pro-gastrin-releasing peptide (ProGRP) concentrations in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008